Acadia Pharmaceuticals (ACAD) is back in focus after a packed early November, combining stronger third quarter revenue, higher full year guidance, fresh data updates and a live patent appeal that shapes Nuplazid’s protection timeline.
Despite the solid revenue print and raised 2026 guidance, Acadia Pharmaceuticals’ share price has been under pressure, with the 90 day share price return down 34.95% and the year to date share price return down 30.13%. The 1 year total shareholder return has declined 22.29% as investors weigh stronger Nuplazid and Daybue sales, remlifanserin updates and the Nuplazid patent appeal against weaker profitability and legal uncertainty.
Scan how the market is treating Acadia Pharmaceuticals alongside other pressured healthcare names that still have solid fundamentals using the curated list of solid balance sheet and fundamentals (23 results)
Acadia Pharmaceuticals trades at a steep discount to both intrinsic estimates and analyst targets after a sharp slide in 2026. Is that a clear pricing mistake or a fair response to patent and profitability risks?
Most Popular Narrative: 40% Undervalued
On the analyst consensus Narrative on Simply Wall St, Acadia Pharmaceuticals screens as undervalued, with a fair value of $30.53 against a last close of $18.37. That gap reflects a more optimistic set of cash flow and earnings assumptions than the current share price implies.
The main thing that has to go right is successful execution on DAYBUE lifecycle expansion and remlifanserin development, including EU and Japan rollout for trofinetide and an effective Phase III program after the mixed but directionally positive RADIANT Phase II readout.
See why 57 investors see Acadia Pharmaceuticals as 40% undervalued.
Result: Fair Value of $30.53 (UNDERVALUED)
Still, the narrative around Acadia Pharmaceuticals can shift quickly if remlifanserin Phase 3 data disappoints, or if DAYBUE and NUPLAZID underperform the revenue paths analysts are assuming.
Find out about the key risks to this Acadia Pharmaceuticals narrative.
Next Steps
The story so far is mixed, with clear risks on one side and meaningful potential on the other. Move quickly, review the details carefully, and evaluate both using the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Acadia Pharmaceuticals?
If Acadia Pharmaceuticals has you thinking harder about risk, reward and timing, broaden your watchlist with a few targeted stock ideas built from clear fundamentals.
- Target resilient balance sheets by scanning a curated list of solid balance sheet and fundamentals (23 results) that can help you focus on financially sturdier businesses when markets turn jumpy.
- Hunt for potential mispricings using the 32 high quality undervalued stocks and quickly compare companies where current prices differ from underlying fundamentals.
- Lock in income-focused ideas through the 6 dividend fortresses and zero in on businesses offering higher yields with an emphasis on stability.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com